Clinical Study on the Use of Huaier Granules for the Treatment of Proteinuria Related to Bevacizumab and Anlotinib in Lung Cancer Patients

Sponsor
Fudan University
Study ID
NCT07358520
Phase
PHASE4
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Proteinuria

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Huaier Granule — DRUG
    Take orally, 10g each time, three times daily.
  • Anlotinib and Bevacizumab — DRUG
    Administer according to clinical routine practice. Refer to the respective drug prescribing information for specific usage.

Study Details

This study is a prospective, multicenter, parallel-controlled clinical trial designed to evaluate the therapeutic efficacy of Huaier Granules for proteinuria occurring in lung cancer patients undergoing treatment with either Bevacizumab or Anlotinib.

Key Dates

First listed
Jan 22, 2026
Start date
Jan 28, 2026
Status verified
Jan 2026
Primary completion
Jan 28, 2027
Completion
Jan 28, 2028

Study Design

Enrollment
40 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Huaier Granules
    Take orally, 10g each time, three times a day. Participants in the experimental group should continue treatment for at least 24 weeks or until treatment failure, intolerable toxicity, withdrawal from the study for any reason, or death, whichever occurs first; or until the investigator determines that there is no further benefit. For specific usage, refer to the drug instructions.
  • Active Comparator: Anlotinib and Bevacizumab
    Administer according to clinical routine practice. Refer to the respective drug prescribing information for specific usage. Continue treatment until disease progression, intolerable toxicity, withdrawal from the study for any reason, or death, whichever occurs first.

Primary Outcome Measure

16-week Efficacy Rate for Proteinuria Treatment [ Time Frame: Start of treatment until 16-week follow-up ]

Central Contacts

Related Studies